HALEON PLC 8.3% potential upside indicated by Barclays

HALEON PLC with ticker (LON:HLN) now has a potential upside of 8.3% according to Barclays.



Barclays set a target price of 383 GBX for the company, which when compared to the HALEON PLC share price of 354 GBX at opening today (21/04/2023) indicates a potential upside of 8.3%. Trading has ranged between 241 (52 week low) and 356 (52 week high) with an average of 14,546,209 shares exchanging hands daily. The market capitalisation at the time of writing is £32,856,844,254.

Haleon plc is a consumer healthcare company. The Company’s product portfolio is divided among five categories: Oral Health; Pain Relief; vitamins, minerals and supplements (VMS); Respiratory Health; Digestive Health, and Other. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax and Centrum. In addition, the Company also has local strategic brands, which include TUMS, ENO, Flonase, ChapStick, Emergen-C, Fenbid, Grand-Pa, and Dr.BEST. The Company operates its business units in three regions: North America; Europe, Middle East, and Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC).